Just reported
From Mimedx's results release of 2026年10月28日; its quarterly report has since been filed.
Actual
US$62.3M
-45% y/y
-3.2% q/q
Guided
—
No guide given
Actual
-US$0.06
Guided
—
No guide given
Actual
-US$11.7M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Mimedx is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
基于 Mimedx Group, Inc. 自己向美国证券交易委员会(SEC)提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
US$3.21-0.6%11月13日 收盘
数据截至2026年9月30日,来自2026年10月28日提交的10-Q
公司指引:2026 财年营收 US$260M 至 US$290M — 同比下降 34.3%(上年同期 US$418.6M)
Grade F
价格下方的色带显示每个日期的评级,仅依据当时已公开的文件计算。
显示 Mimedx Group, Inc. 评级历史 33 个季度中的 2 个。 其余 31 个可回溯到 2016年11月。